Women more sensitive than men to sublingual zolpidem

Women more sensitive than men to sublingual zolpidem

(HealthDay)—Clearance of zolpidem (administered as a sublingual tablet; ZST) is lower in females compared to males, according to a study published in the March issue of The Journal of Clinical Pharmacology.

David J. Greenblatt, M.D., from the Tufts University School of Medicine in Boston, and colleagues evaluated the effect of dose and gender on the pharmacokinetics (PK) and pharmacodynamics (PD) of zolpidem in healthy nonelderly male and female volunteers (11 and 13 males). Participants received a single morning dose of ZST (1.0, 1.75, and 3.5 mg) or placebo.

The researchers found that, in male and female subjects, ZST PK were linear, with area under the curve (AUC) proportional to dose. Oral clearance and elimination half-life was independent of dose; however, in females, the AUC averaged 40 to 50 percent higher, compared to males receiving the same dose. Body weight incompletely explained the gender effect. In females, particularly at the 3.5-mg dose, ZST produced PD changes consistent with benzodiazepine agonist effects. PD effects were significantly related to plasma zolpidem concentrations for several PD variables when data were aggregated across subjects, although there was variability in individuals' response. Regardless of plasma concentration, PD effects of zolpidem seldom differed from placebo in men.

"PD effects of zolpidem from ZST are greater in female subjects, due to a combination of higher plasma concentrations and greater intrinsic sensitivity," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Transcept Pharmaceuticals, which funded the study and is a manufacturer of .

More information: Abstract
Full Text

add to favorites email to friend print save as pdf

Related Stories

US approves drug for middle-of-the-night insomniacs

Nov 23, 2011

The US Food and Drug Administration, for the first time, approved Wednesday medication specifically designed for those who wake up in the middle of the night and cannot fall back to sleep.

FDA: lower ambien's dose to prevent drowsy driving

May 15, 2013

(HealthDay)—The U.S. Food and Drug Administration has approved new, lower-dose labeling for the popular sleep drug Ambien (zolpidem) in an effort to cut down on daytime drowsiness that could be a hazard ...

FDA requires lower doses for sleep medications (Update)

Jan 10, 2013

(HealthDay)—The U.S. Food and Drug Administration announced Thursday that it is asking manufacturers of sleep medications containing zolpidem—including Ambien—to lower the recommended doses and to provide ...

Recommended for you

Using computers to design drugs

12 hours ago

Designing a new medicine is an expensive and time consuming business. Typically it takes around $2 billion and ten years for a new drug to move from its initial design in the lab, to the clinic. All the ...

Lilly psoriasis drug fares well in late-stage test

17 hours ago

Drugmaker Eli Lilly and Co. said its potential psoriasis treatment fared better than both a fake drug and a competitor's product during late-stage testing on patients with the most common form of the skin disease.

New US restrictions on painkiller to take effect

Aug 21, 2014

The federal government is finalizing new restrictions on hundreds of medicines containing hydrocodone, the highly addictive painkiller that has grown into the most widely prescribed drug in the U.S.

User comments